Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Upa pai 1"'
Publikováno v:
Gynécologie Obstétrique Fertilité & Sénologie
Gynécologie Obstétrique Fertilité & Sénologie, 2021, ⟨10.1016/j.gofs.2021.10.003⟩
Gynécologie Obstétrique Fertilité & Sénologie, 2021, ⟨10.1016/j.gofs.2021.10.003⟩
Resume Objectif. Le dosage d’uPA/PAI-1 et le test EPClin® s’ajoutent aux criteres clinico-pathologiques pour poser l’indication d’une chimiotherapie adjuvante dans le traitement des cancers du sein invasifs de pronostic intermediaire. Notre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c0f9786a77d1d986a197b255a55e05
https://doi.org/10.1016/j.gofs.2021.10.003
https://doi.org/10.1016/j.gofs.2021.10.003
Publikováno v:
Miscellaneous.
Introduction/Background* Breast cancer is uncommon in young women in developed countries. It is very heterogenous disease and studies showed, that young patients often have biologically complex and often more agressive tumours. However, little is kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a88eb2c39acb0e36423361ef358535a
https://doi.org/10.1136/ijgc-2021-esgo.255
https://doi.org/10.1136/ijgc-2021-esgo.255
Autor:
Sébastien Molière, Alberto Guggiola, Jean-Marc Lessinger, Suzanne Leblanc, Victor Gabriele, Jean-Pierre Bellocq, Fabien Alpy, Louise Scheer, Stéphane Jankowski, Massimo Lodi, Elisabeth Luporsi, Julie-Charlotte Benabu, Issam Ibnouhsein, Marie-Pierre Chenard, Carole Mathelin, Catherine Tomasetto, Nathalie Reix, Karl Neuberger
Publikováno v:
Clinical Chemistry and Laboratory Medicine
Clinical Chemistry and Laboratory Medicine, De Gruyter, 2019, 57 (6), pp.901-910. ⟨10.1515/cclm-2018-1065⟩
Clinical Chemistry and Laboratory Medicine, De Gruyter, 2019, 57 (6), pp.901-910. ⟨10.1515/cclm-2018-1065⟩
Background uPA and PAI-1 are breast cancer biomarkers that evaluate the benefit of chemotherapy (CT) for HER2-negative, estrogen receptor-positive, low or intermediate grade patients. Our objectives were to observe clinical routine use of uPA/PAI-1 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7e47a0dcd743d1bb10bb2a6cbee56e
https://doi.org/10.1515/cclm-2018-1065
https://doi.org/10.1515/cclm-2018-1065
Autor:
S. Thezenas, P.-E. Colombo, Marian Gutowski, P-J Lamy, William Jacot, Gilles Romieu, Marie Viala, Marie Alexandre, Frédéric Bibeau, Séverine Guiu
Publikováno v:
Cancer Research. 77:P6-09
Purpose: Intermediate-risk early breast cancer (EBC) is a heterogeneous group in which adjuvant chemotherapy decision prove to be difficult. Clinical and pathological criteria might be insufficient to determine the best therapeutic options for patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e35ebb4efe9100f89db28a0a916b95ea
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-28
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-28
Autor:
Jutta John, Edith Weigert, Volker Hanf, C. Thomssen, Christoph Uleer, Carolin Hartung, T Lantzsch, Susanne Peschel, K-F Bürrig, EJ Kantelhardt, Martina Vetter, Joerg Buchmann
Publikováno v:
Cancer Research. 77:P2-05
Introduction The PiA-study (Prognostic assessment in routine Application, NCT 01592825) was designed as a representative cohort of breast cancer patients to estimate the proportions of traditional and modern prognostic factors. The ASCO-recommended b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49a09a1f11a2cc767badcb1d155b5659
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-12
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-12
Autor:
N. Saidi, Sophie Leobon, Y. Aubard, I. Jammet, Véronique Fermeaux, Nicole Tubiana-Mathieu, L. Venat-Bouvet, E. Deluche
Publikováno v:
Cancer Research. 77:P2-05
Background: Adjuvant chemotherapy decisions are relatively simple using clinicopathological parameters (Goldhirsch et al. 2007), some cases require the addition of biomarkers as in patients with node negative or micrometastatic (N0), grade II (GII) b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30b82f8721c8efa2de64097f60ef4bed
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-26
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-26
Autor:
Reinhard Hoffmann, Thomas Kröncke, Benedikt Martin, Gerhard Schenkirsch, Thomas Jung, Jörg Kriegsmann, Bruno Märkl, Elzbieta Jakubowicz, Dieter Steinfeld, Roman Steierl
We retrospectively investigated concordance of EndoPredict (EPclin) with urokinase plasminogen activator and plasminogen activator inhibitor-1 (uPA/PAI-1) in 72 breast cancer patients and compared the results with grading, molecular subtype and chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b144ec04b61045a362eb12e5ecfd6530
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/56344
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/56344
Autor:
Manuela A. Joore, Volker R. Jacobs, Chafika Mazouni, Nadia Harbeck, Ariane Dunant, Julia Bonastre, Ronald E. Kates, Bram Ramaekers, Sophie Marguet
Publikováno v:
European Journal of Cancer, 63, 168-179. ELSEVIER SCI LTD
Background This study investigated the cost effectiveness of guideline-recommended (American Society of Clinical Oncology, European Society of Medical Oncology) urokinase plasminogen activator (uPA)/plasminogen activator inhibitor-1 (PAI-1) biomarker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6863c378a2388a699a680c524d40ba
https://doi.org/10.1016/j.ejca.2016.05.013
https://doi.org/10.1016/j.ejca.2016.05.013
Publikováno v:
Open Life Sciences, Vol 11, Iss 1, Pp 498-505 (2016)
The present study focuses on the effects and suggests possible mechanisms of the traditional Chinese medicine Dilong as compared to dexamethasone on lower respiratory tract remodeling in rats with asthma. The number of leukocytes and eosinophils in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a54bd6fc6a00d4f4121cfaae6b1c29
https://doi.org/10.1515/biol-2016-0064
https://doi.org/10.1515/biol-2016-0064
Autor:
Yves Aubard, J. Mollard, Sophie Leobon, Véronique Fermeaux, Nadira Saidi, Laurence Venat-Bouvet, Isabelle Jammet, Nicole Tubiana-Mathieu, Elise Deluche
Publikováno v:
BMC Cancer
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Background The objective of this study was to compare the efficacy of biomarkers in assessing the risk of breast cancer recurrence in patients with node-negative or micrometastatic grade II breast cancer. Specifically, we compared risk assessments ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37929d1d749def31b5dd3d812565286
https://doi.org/10.1186/s12885-017-3648-z
https://doi.org/10.1186/s12885-017-3648-z